

CITATION REPORT

List of articles citing

Parkinson s disease symptoms: the patient s perspective

DOI: 10.1002/mds.23135

Movement Disorders, 2010, 25, 1646-51.

Source: <https://exaly.com/paper-pdf/48256637/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
416	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease. 2011 , 394-408		
415	Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. 2011 , 310, 139-43		23
414	Fatigue in Parkinson's disease. 2011 , 12, 1999-2007		50
413	Moving towards patient-centered healthcare for patients with Parkinson's disease. 2011 , 17, 360-4		97
412	The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. 2011 , 17, 625-8		70
411	Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. 2011 , 35, 1795-807		8
410	Olfactory loss in Parkinson's disease. 2011 , 2011, 450939		50
409	Serotonergic dysfunction in Parkinson's disease and its relevance to disability. 2011 , 11, 1726-34		62
408	Pathophysiology of diurnal drooling in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1670-6	7	45
407	Multidisciplinary care for Parkinson's disease: not if, but how!. 2011 , 87, 575-8		16
406	Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. 2011 , 17, 318-24		6
405	Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review. 2011 , 121, 485-9		1
404	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. 2012 , 4, 128ra41		92
403	Therapies in Parkinson's disease. 2012 , 25, 433-47		141
402	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. 2012 , 135, 2449-57		52
401	Sleep disorders in Parkinson's disease: many causes, few therapeutic options. 2012 , 314, 12-9		67
400	Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: the case for a higher priority and stronger evidence. 2012 , 18 Suppl 1, S110-3		16

399	Positron emission tomography imaging in neurological disorders. 2012 , 259, 1769-80		58
398	The conceptual framework of palliative care applied to advanced Parkinson's disease. 2012 , 18 Suppl 3, S2-5		16
397	Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey. 2012 , 28, 1239-46		13
396	Pains in Parkinson disease--many syndromes under one umbrella. 2012 , 8, 284-94		151
395	Management of pain in Parkinson's disease. 2012 , 26, 937-48		43
394	In vivo imaging of the integration and function of nigral grafts in clinical trials. 2012 , 200, 199-220		14
393	Progression of motor symptoms in Parkinson's disease. 2012 , 28, 39-48		87
392	Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. 2012 , 19, 402-10		36
391	Pain in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 485-91	7	142
390	Motor Function in MPTP-Treated Tree Shrews (<i>Tupaia belangeri chinensis</i>). 2013 , 38, 1935		14
389	Rasagiline treatment effects on parkinsonian tremor. 2013 , 123, 859-65		7
388	Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach. 2013 , 260, 2951-8		25
387	Sleep and non-motor symptoms in Parkinson's disease. 2013 , 120, 565-9		29
386	Effects of rasagiline on olfactory function in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 2023-7	7	17
385	Moving from physician-centered care towards patient-centered care for Parkinson's disease patients. 2013 , 19, 923-7		79
384	Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. 2013 , 110, 63-73		38
383	How pain arises in Parkinson's disease?. 2013 , 20, 1517-23		39
382	Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT). 2013 , 12, 947-56		80

381	Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson's disease: a randomised controlled pilot study. 2013 , 13, 357	19
380	Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease. 2013 , 260, 3077-85	21
379	The epidemiology of pain in Parkinson's disease. 2013 , 120, 583-6	30
378	Sleep matters in Parkinson's disease: use of a priority list to assess the presence of sleep disturbances. 2013 , 20, 259-65	10
377	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. 2013 , 19, 339-45	77
376	Effectiveness of botulinum toxin B in the treatment of drooling. 2013 , 51, 783-5	8
375	Pain in Parkinson disease: a review of the literature. 2013 , 19, 285-94; discussion 285	102
374	The cerebellum in Parkinson's disease. 2013 , 136, 696-709	427
373	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. 2013 , 12, 346-56	149
372	Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. 2013 , 4, 25-36	57
371	Management of dysphagia and drooling in patients with Parkinson's disease. 2013 , 3, 71-79	6
370	Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. 2013 , 40, 663-9	28
369	Composite brains: toward a systems theory of neural reconstruction. 2013 , 22, 381-91	2
368	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. 2013 , 8, e57221	73
367	Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. 2014 , 2014, 475854	20
366	Treatment of advanced Parkinson's disease. 2014 , 27, 450-60	52
365	Anxiety and depression in Parkinson's disease. 2014 , 16, 285	32
364	Dyskinesias in Parkinson's disease: views from positron emission tomography studies. 2014 , 21, 694-9, e39-43	9

363	How to organize multispecialty care for patients with Parkinson's disease. 2014 , 20 Suppl 1, S167-73	40
362	Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders. 2014 , 121 Suppl 1, S25-31	6
361	Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. 2014 , 121 Suppl 1, S59-68	52
360	Early DEtection of wEaring off in Parkinson disease: the DEEP study. 2014 , 20, 204-11	90
359	Neuroimaging in Parkinson disease: from research setting to clinical practice. 2014 , 10, 708-22	158
358	Proceedings: cell therapies for Parkinson's disease from discovery to clinic. 2014 , 3, 979-91	7
357	Correlates of quality of sexual life in male and female patients with Parkinson disease and their partners. 2014 , 20, 1085-8	26
356	Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. 2014 , 14, 42	42
355	Profile of idiopathic parkinson's disease in Moroccan patients. 2014 , 7, 10	4
354	A rare case of Parkinson's disease with severe neck pain owing to crowned dens syndrome. 2014 , 6, 149-55	2
353	. 2014 ,	3
352	Non-motor symptoms: the core of multi-morbid Parkinson's disease. 2014 , 75, 18-24	32
351	Exploring Issues Around Wearing-off and Quality of Life: The OFF-PARK Survey of People with Parkinson's Disease and their Care Partners. 2015 , 5, 533-9	19
350	Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. 2015 , 2, 357-364	29
349	Olfactory function in Parkinson's Disease - effects of training. 2015 , 132, 395-400	20
348	A new scale for the assessment of pain in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1589-90	7
347	Survey of Health Care Workers Suggests Unmet Palliative Care Needs in Parkinson's Disease. 2015 , 2, 142-148	10
346	The Clinical Evaluation of Parkinson's Tremor. 2015 , 5, 471-4	38

345	Subjective Experiences of Speech and Language Therapy in Patients with Parkinson's Disease: A Pilot Study. 2015 , 2015, 839895	6
344	Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes. 2015 , 2015, 379482	36
343	Web-enabled software for clinical telegaming evaluation of multisensory integration and response to auditory and visual stimuli. 2015 ,	
342	Transitions in Parkinson's disease in primary care: protocol of a longitudinal mixed methods study. 2015 , 5, e007171	6
341	Catechol-O-methyltransferase inhibitors in Parkinson's disease. 2015 , 75, 157-74	98
340	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain. 2015 , 262, 2164-70	31
339	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. 2015 , 21, 287-91	72
338	The matter of 'fidelity': Keep it simple or complex?. 2015 , 29, 21-5	10
337	Aktuelle Strategien gegen Schmerzen bei Morbus Parkinson. 2015 , 17, 44-52	
336	Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial. 2015 , 29, 341-50	24
335	Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. 2015 , 299, 156-74	33
334	Quality of life in patients with PD and their caregiving spouses: A view from both sides. 2015 , 139, 24-8	6
333	Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson's disease. 2015 , 21, 61-7	23
332	Serotonin in Parkinson's disease. 2015 , 277, 136-45	167
331	Drosophila Mutant Model of Parkinson's Disease Revealed an Unexpected Olfactory Performance: Morphofunctional Evidences. 2016 , 2016, 3508073	3
330	Aerobic Exercise Preserves Olfaction Function in Individuals with Parkinson's Disease. 2016 , 2016, 9725089	56
329	Emerging approaches in Parkinson's disease - adjunctive role of safinamide. 2016 , 12, 1151-60	5
328	Classification and Characteristics of Pain Associated with Parkinson's Disease. 2016 , 2016, 6067132	17

327	Pain management in patients with Parkinson's disease: challenges and solutions. 2016 , 9, 469-479	49
326	Impact of sleep quality on the quality of life of patients with Parkinson's disease: a questionnaire based study. 2016 , 148, 29-34	24
325	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016 , 31, 1095-102	7 186
324	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. 2016 , 56, 852-61	64
323	Chronic pain in Parkinson's disease: Frequency, characteristics, independent factors, and relationship with health-related quality of life. 2016 ,	20
322	A Japanese multicenter survey characterizing pain in Parkinson's disease. 2016 , 365, 162-6	5
321	A Critical Evaluation of the Methodological Obstacles to Translating Cell-Based Research Into an Effective Treatment for People With Parkinson's Disease. 2016 , 30, 845-53	2
320	Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. 2016 , 6, 385-98	2
319	Imaging in Parkinson's disease. 2016 , 16, 371-5	55
318	Novel multifunctional dopamine D/D receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties. 2016 , 24, 5088-5102	15
317	Botulinum toxin for drooling in Parkinson's disease. 2016 ,	4
316	Clinical Presentation of Anxiety in Parkinson's Disease: A Scoping Review. 2016 , 36, 134-47	13
315	Management of autonomic dysfunction in Parkinson's disease. 93-110	2
314	Management of pain and neuromuscular complications in Parkinson's disease. 162-174	
313	Microglia-Mediated Inflammation and Neurodegenerative Disease. 2016 , 53, 6709-6715	139
312	The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. 2016 , 39, 88-93	2
311	Choral singing therapy following stroke or Parkinson's disease: an exploration of participants' experiences. 2016 , 38, 952-62	37
310	Integrating Patient Concerns into Parkinson's Disease Management. 2017 , 17, 3	28

309	Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor. 2017 , 23, 209-215	54
308	[Emergency medical training through simulation : Always the same for everyone?]. 2017 , 66, 189-194	6
307	Acceptance of technology-based tools in a sample of Parkinson's patients. 2017 , 13, 3-13	1
306	Non-motor features of Parkinson disease. 2017 , 18, 435-450	621
305	Disability from pain directly correlated with depression in Parkinson's disease. 2017 , 160, 1-4	22
304	Reliability and validity study of a Turkish version of the fatigue severity scale in Parkinson's disease patients. 2017 , 40, 185-190	9
303	The Nonmotor Features of Parkinson's Disease. 2017 , 132, 33-54	42
302	Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease. 2017 , 13, 1744806917691525	19
301	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. 2017 , 49, 1-17	19
300	Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease. 2017 , 18, 1457-1465	6
299	What can the treatment of Parkinson's disease learn from dementia care; applying a bio-psycho-social approach to Parkinson's disease. 2017 , 12, e12159	2
298	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. 2017 , 8, 44-53	7
297	Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway. 2017 , 359, 224-247	21
296	Clinical Assessments in Parkinson's Disease: Scales and Monitoring. 2017 , 132, 129-182	41
295	Palliative Care for Patients and Families With Parkinson's Disease. 2017 , 132, 475-509	10
294	Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. 2017 , 92, 1359-1367	32
293	Sleep Dysfunction in Parkinson's Disease. 2017 , 133, 719-742	24
292	Sexual Preoccupation Behavior in Parkinson's Disease. 2017 , 7, 175-182	12

291	Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. 2017 , 124, 1529-1537	34
290	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. 2017 , 3, 5	23
289	A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. 2017 , 35, 33-50	156
288	The patient's perspective: The effect of levodopa on Parkinson symptoms. 2017 , 35, 48-54	18
287	Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. 2017 , 129, 46-54	9
286	Distinguishing Different Stages of Parkinson's Disease Using Composite Index of Speed and Pen-Pressure of Sketching a Spiral. 2017 , 8, 435	38
285	Imaging the Nonmotor Symptoms in Parkinson's Disease. 2017 , 133, 179-257	9
284	Wrist sensor-based tremor severity quantification in Parkinson's disease using convolutional neural network. 2018 , 95, 140-146	45
283	Pain in Parkinson's disease: facts and uncertainties. 2018 , 25, 917-e69	46
282	BEWARE: Behandeling van aan wearing-off gerelateerde stress voor mensen met de ziekte van Parkinson. 2018 , 22, 33-36	
281	Sleep-Wake Disorders in Late Life. 2018 , 511-534	
280	Family Therapy with Couples and Individuals with Parkinson's Disease. 2018 , 40, 299-308	2
279	Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease. 2018 , 50, 10-18	21
278	Impact of motor fluctuations on real-life gait in Parkinson's patients. 2018 , 62, 388-394	12
277	Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats. 2018 , 34, 799-807	7
276	Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. 2018 , 387, 220-227	27
275	Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease. 2018 , 26, 150-161	20
274	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. 2018 , 5, 6-13	14

273	Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease. 2018 , 25, 307-312	18
272	Predictive risk factors for chronic low back pain in Parkinson's disease. 2018 , 164, 190-195	9
271	Effects of Exercise on Non-motor Symptoms in Parkinson's Disease. 2018 , 40, 8-15	46
270	Advances in Parkinson's Disease: 200 Years Later. 2018 , 12, 113	65
269	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. 2018 , 2018, 4327597	10
268	Neuroimaging of Sleep Disturbances in Movement Disorders. 2018 , 9, 767	9
267	Management of Neurogenic Sexual Dysfunction. 224-235	
266	Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. 2018 , 35, 1041-1054	16
265	The prevalence of chronic low back pain and lumbar deformities in patients with Parkinson's disease: implications on spinal surgery. 2018 , 27, 2847-2853	10
264	Assessing the Efficacy of Cell Transplantation for Parkinson's Disease: A Patient-Centered Approach. 2018 , 8, 375-383	2
263	Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease. 2018 , 265, 1764-1771	40
262	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. 2018 , 25, 1255-1261	14
261	Peripheral neuropathic pain in idiopathic Parkinson's disease: Prevalence and impact on quality of life; a case controlled study. 2018 , 392, 3-7	15
260	Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. <i>Movement Disorders</i> , 2018 , 33, 909-919	7 56
259	Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience. 2018 , 10,	13
258	Inhibition of microRNA-505 suppressed MPP+ -induced cytotoxicity of SHSY5Y cells in an in vitro Parkinson's disease model. 2018 , 835, 11-18	16
257	Understanding, Impact, and Communication of "Off" Periods in Parkinson's Disease: A Scoping Review. 2018 , 5, 461-470	8
256	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. 2018 , 91, e894-e905	71

255	Impact of Tremor on Patients With Early Stage Parkinson's Disease. 2018 , 9, 628	13
254	ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinson's Disease. 2018 , 98, 1155-1169.e6	47
253	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. 2018 , 56, 27-32	49
252	Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder. 2019 , 129, 55-93	30
251	L-DOPA for Parkinson's disease-a bittersweet pill. 2019 , 49, 384-398	22
250	Addressing sexuality and intimacy in people living with Parkinson's during palliative care and at the end of life. 2019 , 28, 772-779	1
249	Patient and physician perceptions of disease management in Parkinson's disease: results from a US-based multicenter survey. 2019 , 15, 1487-1495	6
248	The challenge of pain in the pharmacological management of Parkinson's disease. 2019 , 20, 1847-1854	13
247	Occupational therapists' perceptions of psychosocial strategies for clients with Parkinson's disease. 2019 , 21, 479-486	1
246	Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. 2019 , 18, 1203-1218	19
245	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. 2019 , 20, 55	6
244	Effects of Parkinson's on employment, cost of care, and quality of life of people with condition and family caregivers in the UK: a systematic literature review. 2019 , 10, 321-333	2
243	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. 2019 , 269, 121-133	26
242	The roles of galectin-3 and galectin-4 in the idiopathic Parkinson disease and its progression. 2019 , 184, 105373	12
241	Serum N-Glycosylation in Parkinson's Disease: A Novel Approach for Potential Alterations. 2019 , 24,	15
240	Computational polymorph screening reveals late-appearing and poorly-soluble form of rotigotine. 2019 , 2,	24
239	Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease. 2019 , 414, 8-27	12
238	The influence of posture duration on hand tremor during tasks with attention-distraction in persons with Parkinson's disease. 2019 , 16, 61	1

237	Using wearables to assess bradykinesia and rigidity in patients with Parkinson's disease: a focused, narrative review of the literature. 2019 , 126, 699-710		23
236	Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson's Disease. 2019 , 9, 369-378		6
235	Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2019 , 34, 816-819	7	30
234	Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients. 2019 , 36, 511-530		23
233	Revisiting eligibility for deep brain stimulation: Do preoperative mood symptoms predict outcomes in Parkinson's disease patients?. 2019 , 63, 131-136		2
232	Clinical social work in the care of Parkinson's disease: role, functions, and opportunities in integrated health care. 2019 , 58, 108-125		3
231	Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease. 2019 , 1, 27		1
230	Challenges of Parkinson's Disease. 2019 ,		3
229	Serotonergic dysfunction in a model of parkinsonism induced by reserpine. 2019 , 96, 73-78		6
228	Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales. 2019 , 22, 215-225		7
227	Identifying barriers to help-seeking for non-motor symptoms in people with Parkinson's disease. 2019 , 24, 561-571		7
226	Widespread Pressure Pain Hyperalgesia Is Not Related to Pain in Patients with Parkinson's Disease. 2020 , 21, 232-238		1
225	Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. 2020 , 163, 107808		17
224	Respiratory repercussions of neurological diseases and how best to manage them. 2020 , 14, 89-102		0
223	Assessment of copper, iron, zinc and manganese status and speciation in patients with Parkinson's disease: A pilot study. 2020 , 59, 126423		19
222	Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson's disease. 2020 , 25, 392-405		6
221	Estimation of Parkinson's disease severity from voice features of vowels and consonant. 2020 , 2020, 3666-3669		1
220	Living with Parkinson's disease: The benefits of community programming. 2020 , 41, 101241		0

219	Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease. 2020 , 199, 106257	3
218	Sialorrhea in Parkinson's Disease. 2020 , 12,	5
217	Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem. 2020 , 17, 1914-1925	8
216	Functional Recovery in Parkinson's Disease: Current State and Future Perspective. 2020 , 9,	
215	Examining the use of sharp-free subcutaneous infusion devices with apomorphine. 2020 , 16, 2-6	1
214	Neuroprotective Properties of Green Tea () in Parkinson's Disease: A Review. 2020 , 25,	22
213	Index. 2020 , 333-340	
212	Preface. 2020 , xiii-xv	
211	Editors' Note. 2020 , xvii-xvii	
210	Alzheimer's Dementia. 2020 , 1-19	
209	Primary Progressive Aphasia. 2020 , 20-42	0
208	Vascular Dementia. 2020 , 43-67	
207	Mild Cognitive Impairment. 2020 , 68-94	
206	Parkinson's Disease Dementia. 2020 , 95-132	
205	Huntington's Disease. 2020 , 133-166	
204	Progressive Supranuclear Palsy. 2020 , 167-192	
203	Answers to Exercises. 2020 , 221-239	
202	Test Protocol. 2020 , 240-243	

201 Test Material. **2020**, 244-245

200 Glossary. **2020**, 246-289

199 Bibliography. **2020**, 290-332

198 Preface. **2020**, xi-xii

197 What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. **2020**, 202-212

196 Multiple Sclerosis. **2020**, 193-220

195 Epidemiology and Mental Health in Old Age. **2020**, 5-23

194 Vascular Dementia. **2020**, 24-37

193 Young-Onset Dementias. **2020**, 38-49

192 Rare and Unusual Dementias. **2020**, 50-77

191 Mania in Late Life. **2020**, 78-91

190 Alcohol Misuse in Older People. **2020**, 92-104

189 Drug Misuse in Older People. **2020**, 105-115

188 Mental Health in Parkinson's Disease. **2020**, 116-128

187 The Home Assessment in Old Age Psychiatry. **2020**, 129-138

186 Driving in Dementia. **2020**, 139-148

185 Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. **2020**, 149-160

184 Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. **2020**, 161-172

183 To Scan or Not to Scan. **2020**, 173-190

182 Supporting Self-Management in Early Dementia. **2020**, 191-201

181 Psychosocial Interventions in Dementia. **2020**, 213-222

180 Palliative Care in Dementia. **2020**, 223-242

179 Review of Treatment for Late-Life Depression. **2020**, 243-253

178 Reducing the Healthcare Burden of Delirium. **2020**, 254-265

177 Controlling the Confusion. **2020**, 266-278

176 Residence Capacity. **2020**, 305-316

175 Concluding Reflections. **2020**, 328-329

174 Index. **2020**, 330-344

173 Introductory Comments. **2020**, 1-4

172 Mental Health Laws from All UK Jurisdictions. **2020**, 279-292

171 Deprivation of Liberty. **2020**, 293-304

170 Understanding the Person with Dementia. **2020**, 317-327

169 Potential Role of Natural Polyphenols against Protein Aggregation Toxicity: In Vitro, In Vivo, and Clinical Studies. **2020**, 11, 2915-2934 14

168 Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies. **2020**, 34, 1149-1163 7

167 Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. **2020**, 80, 775-796 14

166 Management of Pain in Parkinson's Disease. **2020**, 10, S37-S48 13

165	In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385. 2020 , 25,		3
164	Gait Deficits and Loss of Striatal Tyrosine Hydroxylase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease. 2020 , 433, 53-71		12
163	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. 2020 , 72, 82-87		13
162	Dyspnea: A Missing Item of the MDS-UPDRS Part I?. <i>Movement Disorders</i> , 2020 , 35, 1079	7	2
161	Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. 2020 , 35, 955-961		25
160	Parkinson disease clinical subtypes: key features & clinical milestones. 2020 , 7, 1272-1283		13
159	Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. 2020 , 26, 333-342		3
158	Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 947-958	7	30
157	Group-based music intervention in Parkinson's disease - findings from a mixed-methods study. 2020 , 34, 533-544		14
156	Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease. 2020 , 10,		11
155	The Rehapiano-Detecting, Measuring, and Analyzing Action Tremor Using Strain Gauges. 2020 , 20,		1
154	D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. 2020 , 11, 560-566		6
153	Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease. 2020 , 6, 1		42
152	Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies. 2019 , 13, 1381		14
151	Could Heat Therapy Be an Effective Treatment for Alzheimer's and Parkinson's Diseases? A Narrative Review. 2019 , 10, 1556		17
150	Machine learning ensemble for neurological disorders. 2020 , 32, 12697-12714		9
149	Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. 2020 , 77, 461-469		21
148	Pain-Induced Beta Activity in the Subthalamic Nucleus of Parkinson's Disease. 2020 , 98, 193-199		1

147	Understanding patients' and caregivers' perspectives and educational needs in Parkinson's disease: a multi-ethnic Asian study. 2020 , 41, 2831-2842	7	
146	A Comparative Analysis of Machine Learning classifiers for Dysphonia-based classification of Parkinson's Disease. 2021 , 11, 69-83	6	
145	The economic benefit of timely, adequate, and adherence to Parkinson's disease treatment: the Value of Treatment Project 2. 2021 , 28, 707-716	3	
144	Changes of olfactory tract in Parkinson's disease: a DTI tractography study. 2021 , 63, 235-242	6	
143	Effects of Lee Silverman Voice Treatment BIG and conventional physiotherapy on non-motor and motor symptoms in Parkinson's disease: a randomized controlled study comparing three exercise models. 2021 , 14, 1756286420986744	2	
142	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. 2021 , 179, 189-205	1	
141	Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study. 2021 , 2021, 6635618	3	
140	Data analytics for wearable IoT-based telemedicine. 2021 , 357-378	1	
139	Extracellular Vesicles in Neurological Disorders. 2021 , 97, 411-436	0	
138	An automated cloud-based tool for Screening of Parkinson's disease in Bangladesh. 2021 ,	0	
137	Quantifying upper limb motor impairment in people with Parkinson's disease: a physiological profiling approach. 2021 , 9, e10735	2	
136	Molecular Mechanisms Underlying Reciprocal Interactions Between Sleep Disorders and Parkinson's Disease. 2020 , 14, 592989	1	
135	STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson's disease: A meta-analysis of randomized controlled trials. 2021 , 201, 106450	5	
134	One Year Trajectory of Caregiver Burden in Parkinson's Disease and Analysis of Gender-Specific Aspects. 2021 , 11,	7	
133	Upper brainstem GABA levels in Parkinson's disease. 2021 , 34, 689-696	1	
132	Pain in Parkinson's disease: Mechanism-based treatment strategies. 2021 , 15, 108-115	6	
131	The Neurophysiology of Sleep in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1526-1542	7	5
130	Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson's disease. 2021 , 16, e0248800	0	

129	Serious games for Parkinson's Disease management as implemented in PROPHETIC platform. 2021 , 27, 14604582211011231	1
128	Self-tracking in Parkinson's The Lived Efforts of Self-management. 2021 , 5, 1-25	0
127	People with Parkinson's Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?. 2021 , 11, 715-724	5
126	A Validation Study of PROMIS Sleep Disturbance (PROMIS-SD) and Sleep Related Impairment (PROMIS-SRI) Item Banks in Individuals with Idiopathic Parkinson's Disease and Matched Controls. 2021 , 11, 877-883	0
125	Prevalence and profile of nocturnal disturbances in Chinese patients with advanced-stage Parkinson's disease: a cross-sectional epidemiology study. 2021 , 21, 194	0
124	REPRINTED WITH PERMISSION OF IASP [PAIN 162 (2021) 999-1006: Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. 2021 , 22, 46-55	
123	A comprehensive review on the neuropathophysiology of selenium. 2021 , 767, 144329	12
122	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. 2021 , 11, 9611	6
121	Trajectories of pain over 6 years in early Parkinson's disease: ICICLE-PD. 2021 , 268, 4759-4767	0
120	The -Glycome of Human Nigrostriatal Tissue and Its Alteration in Parkinson's Disease. 2021 , 20, 3913-3924	3
119	Healthcare management applications based on triboelectric nanogenerators. 2021 , 9, 060703	6
118	GaborPDNet: Gabor Transformation and Deep Neural Network for Parkinson's Disease Detection Using EEG Signals. 2021 , 10, 1740	10
117	Oral Health Disorders in Parkinson's Disease: More than Meets the Eye. 2021 , 11, 1507-1535	2
116	Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors. 2021 , 11,	2
115	Diagnosis and Management of Pain in Parkinson's Disease: A New Approach. 2021 , 38, 559-577	2
114	Efectividad del trabajo de resistencia y de cicloergómetro a alta velocidad sobre la bradicinesia en la enfermedad de Parkinson: revisión sistemática. 2021 , 43, 230-238	
113	How far can I reach? The perception of upper body action capabilities in Parkinson's disease. 2021 , 83, 3259-3274	
112	A Survey of People With Parkinson's and Their Carers: The Management of Pain in Parkinson's. 2021 , 8919887211023592	1

111	A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. 2021 , 89, 128-133	5
110	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. 2021 , 89, 186-194	3
109	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. 2021 , 11,	10
108	Altered microstructural properties of superficial white matter in patients with Parkinson's disease. 2021 , 1	0
107	Musculoskeletal pain in Parkinson's disease: a narrative review. 2021 , 11, 373-385	
106	The prevalence of pain in Huntington's disease in a large worldwide cohort. 2021 , 89, 73-78	1
105	Non-lesional treatment options for tremor in idiopathic Parkinson syndrome: a protocol for a systematic literature review. 2021 , 11, e048367	
104	Real-World Evidence for a Smartwatch-Based Parkinson's Motor Assessment App for Patients Undergoing Therapy Changes. 2021 , 5, 206-215	1
103	Drooling rating scales in Parkinson's disease: A systematic review. 2021 , 91, 173-180	1
102	Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease. 2021 , 358, 577662	3
101	Translation, adaptation and validation of the Bulgarian version of the King's Parkinson's Disease Pain Scale. 2021 , 21, 357	1
100	Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study. 2021 , 41, 1954-1963	3
99	Ventilatory Impairments Associated with Parkinson's Disease: A Systematic Review and Meta-Analysis. 2021 , 100, 173-181	1
98	Clinical features associated with drooling in Parkinson's disease. 2021 , 42, 895-903	1
97	Gastrointestinal dysfunction in Parkinson's disease. 2021 , 1, 179-208	
96	Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease. 2021 , 6, 23814683211021380	1
95	Parkinsonism. 2021 , 82-120.e21	
94	Language in Dementia. 2020 ,	7

93	Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. 2021 , 162, 999-1006	10
92	Olfactory training in patients with Parkinson's disease. 2013 , 8, e61680	83
91	Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management. 2020 , 15, e0243051	2
90	Capturing nighttime symptoms in Parkinson disease: Technical development and experimental verification of inertial sensors for nocturnal hypokinesia. 2016 , 53, 487-98	18
89	Smartphone-Based Monitoring of Parkinson Disease: Quasi-Experimental Study to Quantify Hand Tremor Severity and Medication Effectiveness. 2020 , 8, e21543	6
88	Specialist rehabilitation for people with Parkinson's disease in the community: a randomised controlled trial. 2014 , 2, 1-376	6
87	Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. 2012 , 7, 611-9	10
86	Application of Deep Learning Models for Automated Identification of Parkinson's Disease: A Review (2011-2021). 2021 , 21,	8
85	Geräteunterstützte Therapien bei fortgeschrittenem idiopathischem Parkinson-Syndrom. 2021 , 40, 803-813	0
84	Utility of GPI+VIM dual-lead deep brain stimulation for Parkinson's disease patients with significant residual tremor on medication. 2021 , 1-7	1
83	Pain in Parkinson Patients. 2015 , 209-219	
82	[Current possibilities of quality of life improvement in the late stages of Parkinson's disease]. 2015 , 115, 94-100	1
81	The Non-motor Parkinson's Disease. 2017 , 117-127	
80	Non-pain Symptoms. 2020 , 533-542	
79	Parkinson's Disease and Hypotensive Syndromes. 2020 , 157-166	
78	Causes of Smell, Taste, and Oral Somatosensory Disorders Affecting Eating and Drinking. 2020 , 1-40	1
77	Detection of signs of Parkinson's disease using dynamical features via an indirect pointing device. 2020 , 53, 16347-16352	
76	Deep Brain Stimulation for Gait and Postural Disturbances in Parkinson's Disease. 2020 , 101-122	1

- 75 Causes of Smell, Taste, and Oral Somatosensory Disorders Affecting Eating and Drinking. **2020**, 1-40
- 74 Smartphone-Based Monitoring of Parkinson Disease: Quasi-Experimental Study to Quantify Hand Tremor Severity and Medication Effectiveness (Preprint).
- 73 Clinical Topics in Old Age Psychiatry. **2020**,
- 72 Automatic Detection of K-Complexes Using the Cohen Class Recursiveness and Reallocation Method and Deep Neural Networks with EEG Signals. **2021**, 21, 0
- 71 Delay in Diagnosis of Cauda Equina Syndrome with a Malfunctioning Spinal Cord Stimulator. **2021**, 22, 1002-1004
- 70 Evidence-Based PET for Neurological Diseases. **2020**, 125-136
- 69 Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson Disease. **2020**, 1-18
- 68 Sleep maintenance insomnia. **2020**, 15-26
- 67 Causes of Smell, Taste, and Oral Somatosensory Disorders Affecting Eating and Drinking. **2020**, 1281-1320 1
- 66 UPDRS Label Assignment by Analyzing Accelerometer Sensor Data Collected from Conventional Smartphones. **2020**, 173-182
- 65 Examining the use of sharp-free subcutaneous infusion devices with apomorphine. **2020**, 16, 215-220
- 64 Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. **2015**, 40, 504-32 119
- 63 Estimation of Severity in Parkinson Disease Using Acoustic Features of Phonatory Tasks. 1-12
- 62 Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain. **2021**, 12, 759679 0
- 61 Predictors of Pain Severity and its Impact on Quality of Life in Patients with Parkinson's Disease. **2021**, 69, 979-983
- 60 A Simple and Effective Approach Based on a Multi-Level Feature Selection for Automated Parkinson's Disease Detection.. **2022**, 12, 1
- 59 Etiologies of insomnia in Parkinson's disease - Lessons from human studies and animal models.. **2022**, 350, 113976 1
- 58 A cross-sectional study of knowledge and practices in the management of patients with Parkinson's disease amongst public practice-based general practitioners and geriatricians.. **2022**, 22, 91

- 39 Parkinson's Disease: An Overview of the Non-Motor Symptomatology. **2022**, 3-17
- 38 SPECT Image Features for Early Detection of Parkinson's Disease using Machine Learning Methods. **2021**, 2021, 2773-2777 0
- 37 Recent Studies on Berry Bioactives and Their Health-Promoting Roles.. **2021**, 27,
- 36 TremorSense: Tremor Detection for Parkinson's Disease Using Convolutional Neural Network. **2021** 0
- 35 The distorted body: The perception of the relative proportions of the body is preserved in Parkinson's disease.. **2022**, 1
- 34 Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson's Disease? A Systematic Review of the Current Literature. **2022**, 12, 513 1
- 33 Parkinson's disease, temporomandibular disorder pain and bruxism and its clinical consequences: a protocol of a single-centre observational outpatient study.. **2022**, 12, e052329
- 32 Apomorphine infusion for improving sleep in Parkinson's disease.. **2022**, 21, 395-398
- 31 THE USE OF EMOTIONAL INTELLIGENCE IN THE TREATMENT OF PARKINSON'S DISEASE AND SOCIAL WORKER IN THE ROLE OF CASE MANAGER.
- 30 An Activity Recognition Framework for Continuous Monitoring of Non-Steady-State Locomotion of Individuals with Parkinson's Disease. **2022**, 12, 4682
- 29 Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study. **2022**, 12, 654
- 28 Levodopa/Entacapone/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. **2022**, 15, 175628642211080 1
- 27 Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey. **2022**, 2022, 1-9
- 26 Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice □ Balancing pharmacological and non-pharmacological approaches. 14, 1
- 25 A generic optimization and learning framework for Parkinson disease via speech and handwritten records. 1
- 24 An innovative biodevice towards monitoring of miR-153 using specific DNA immobilized on the surface of poly(chitosan) decorated AgNPs/GQDs-CysA conductive nano-ink: Early-stage diagnosis of Parkinson's disease using biosensor technology. **2022**, 286, 116017 0
- 23 Characteristics and treatment of pain in Parkinson's disease. **2022**, 0
- 22 Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies. **2022**, 12, 2

- 21 Multidimensional Assessment of Individuals with Parkinson Disease: Development and Structure Validation of a Self-Assessment Questionnaire. **2022**, 10, 1823 ○
- 20 Physical Activity Coaching via Telehealth for People With Parkinson Disease: A Cohort Study. **2022**, 46, 240-250 ○
- 19 Motor imagery vividness and symptom severity in Parkinson's disease. ○
- 18 Community-based high-intensity cycling improves disease symptoms in individuals with Parkinson's disease: A six-month pragmatic observational study. ○
- 17 Sexual needs and sexual function of patients with Parkinson disease. ○
- 16 Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson Disease. **2022**, 2853-2870 ○
- 15 Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson disease. **2023**, 121-150 ○
- 14 Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease. **2023**, 69-104 ○
- 13 New Developments for Parkinson Therapy with COMT Inhibitors. 2-10 ○
- 12 Management of Fluctuating Parkinson Disease: From Science to Clinical Wisdom. 34-39 ○
- 11 Acoustical and Perceptual Analysis of Voice in Individuals with Parkinson Disease. ○
- 10 Understanding the dopaminergic pathway relative to men's sexual dysfunction in patients with Parkinson disease: a narrative review with implications for future research. ○
- 9 Methodically manage pain in older patients with Parkinson disease. ○
- 8 Chronic Pain And Levodopa Therapy in Parkinson Disease Patients. **2022**, 16, ○
- 7 Off-time Treatment Options for Parkinson Disease. 1
- 6 An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson disease using neuromelanin-sensitive MRI. ○
- 5 From OFF to ON—treating OFF Episodes in Parkinson Disease. **2020**, 16, 2 ○
- 4 The mechanism of Parkinson oscillation in the cortex: Possible evidence in a feedback model projecting from the globus pallidus to the cortex. **2023**, 20, 6517-6550 ○

- 3 Vision-based estimation of MDS-UPDRS scores for quantifying Parkinson's disease tremor severity. **2023**, 85, 102754 ○
- 2 The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies. 14, ○
- 1 Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease. 14, ○